Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

NCT06715241 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT06715241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06715241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2024
Completion date
December 31, 2030
Enrollment
77 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cervical cancers